Adicet Bio (ACET) Fundamental Analysis: Revenue, Earnings & Valuation

2.61 / 10

Underperform

Fundamental analysis rates ACET as Underperform with a 2.6/10 score. Liquidity ratios (current liabilities/total liabilities 64.96% and interest coverage 35.1) are acceptable, yet valuation metrics like PB‑ROE and Asset‑MV are unfavorable, indicating selective investment only.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score3/3

Weight39.72%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.55%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.53%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value64.96

Score2/3

Weight1.54%

1M Return0.36%

PB-ROE

Value2.55

Score1/3

Weight32.10%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.08

Score3/3

Weight3.47%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.60%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.22%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.35%

1M Return-1.13%

Asset-MV

Value-0.55

Score1/3

Weight35.89%

1M Return6.31%

Is ACET fundamentally strong?

ACET scores 2.61/10 on fundamentals and holds a Premium valuation at present. Backed by its -67.55% ROE, 0.00% net margin, -0.56 P/E ratio, 0.41 P/B ratio, and 20.53% earnings growth, these metrics solidify its Underperform investment rating.